
19 – 23 October 2026 | Gold Coast

Capital Sprint, is a new fast-paced company presentation format within the Investment & Global Growth stream at the AusBiotech International Conference. Capital Sprint has been designed to give investors a concise view of selected life sciences companies at key capital or commercial inflection points. Apply to present today through the Investor Readiness Platform. Applications close 30 September.


Capital Sprint: Public Markets showcases listed life sciences companies with established market relevance, substantive progress or validation, and significant value-inflection points ahead.
In a series of rapid three-minute, no-slide pitches, selected companies will distil their current market position, key evidence and progress, upcoming catalysts, and pathway to shareholder value creation.
Designed for public-market investors and other capital-market participants, Capital Sprint: Public Markets provides a concise view of listed biotechnology, medtech and health innovation companies with clear upcoming catalysts and a forward-looking capital-market story.
The format is intentionally direct: no slides, no extended corporate presentations, just a concise articulation of what investors should understand about the company now.
Apply to present today through the Investor Readiness Platform. Applications close 30 September.
Event: Wednesday October 21st, 4.30pm
Capital Sprint: Venture showcases private life sciences companies with a well-defined investment proposition, substantive evidence or external validation, and a clear next value-creation milestone. In a series of rapid three-minute, no-slide pitches, selected companies will outline where they are now, the evidence and progress underpinning their opportunity, the next value-inflection point, and the capital required to get there.
Designed for investors and other capital-market participants, Capital Sprint: Venture provides a fast-paced view of biotechnology, medtech and health innovation companies with a credible pathway to their next stage of growth.
The format is intentionally direct: no slides, no long presentations, just a clear articulation of the company, the opportunity, the next milestone and how achieving it creates value.
Apply to present today through the Investor Readiness Platform. Applications close 30 September.
Event: Thursday October 22nd, 3.50pm.
Capital Sprint: Venture is sponsored by Google Cloud

Presenting companies for Capital Sprints will be selected from companies who engage through AusBiotech’s Investor Readiness Platform (IRP) and related investor-readiness processes.
The IRP is open year-round and helps AusBiotech identify companies for investment-focused opportunities across programs and events.
Companies interested in being considered for future opportunities should review the application process.
Position your organisation at the forefront of Australia’s life sciences sector with a BioInnovation Spotlight session.
Located in the heart of the exhibition hall, the BioInnovation Spotlight stage provides a high-impact platform for organisations to showcase breakthrough technologies, products, services, and innovative solutions through a compelling 10-minute presentation to an engaged audience of industry leaders, investors, researchers and decision-makers.
Held during the conference catering breaks, these sessions are designed to maximise visibility, drive meaningful conversations and generate new business opportunities when delegate traffic is at its highest.
Held from 2.15pm on Wednesday October 21st The Early-Stage Innovation Forum, sponsored by West Pharmaceuticals, is designed to help Australia’s most promising life sciences innovations move from discovery towards commercialisation.
Unlike traditional investor pitch events, this forum provides a supportive environment where researchers and founders can showcase their innovation, receive expert feedback and build valuable industry connections before embarking on larger fundraising activities.
Participants may be working on a novel therapeutic, medical device, diagnostic, digital health platform or enabling technology, and will be selected through the Investor Readiness Platform (IRP)